Valeant Pharmaceuticals International (VRX) Posts Q1 EPS of $0.02, Tops Revenue Expectations and Raises FY11 Guidance
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Total costs and expenses: 183.41M
Today's EPS Names:
CGEH, NAKA, APOG, More
Financial Fact:
Total costs and expenses: 183.41M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.02, versus ($0.02) reported last year. Revenue for the quarter came in at $565 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
- Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
